Cited by 21Alzheimer's disease research and treatmentsBacterial biofilms and quorum sensingDementia and Cognitive Impairment Research

APOE ε4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics

Kaufer, Dan, Gandy, Sam·2009·Neurology

Abstract

Antibiotics are losing efficacy due to the rapid evolution and spread of resistance. Treatments targeting bacterial virulence factors have been considered as alternatives because they target virulence instead of pathogen viability, and should therefore exert weaker selection for resistance than conventional antibiotics. However, antivirulence treatments rarely clear infections, which compromises their clinical applications. Here, we explore the potential of combining antivirulence drugs with antibiotics against the opportunistic human pathogen Pseudomonas aeruginosa. We combined two antivirulence compounds (gallium, a siderophore-quencher, and furanone C-30, a quorum sensing-inhibitor) together with four clinically relevant antibiotics (ciprofloxacin, colistin, meropenem, tobramycin) in 9×9 drug concentration matrices. We found that drug-interaction patterns were concentration dependent, with promising levels of synergies occurring at intermediate drug concentrations for certain drug pairs. We then tested whether antivirulence compounds are potent adjuvants, especially when treating antibiotic resistant clones. We found that the addition of antivirulence compounds to antibiotics could restore growth inhibition for most antibiotic resistant clones, and even abrogate or reverse selection for resistance in five drug combination cases. Molecular analyses suggest that selection against resistant clones occurs when resistance mechanisms involve restoration of protein synthesis, but…

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181c6784a

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE ε4 carrier status may limit the response to anti-Aβ passive immunization.

    “Although clinical trials of the Aβ-directed mAb Bapinezumab showed no clear cognitive benefits in patients with mild to moderate AD [42], the results also indicated that APOE ε4 carrier status may limit the response to anti-Aβ passive immunization [43,44], as well as being associated with an increased rate of microbleeds and vasogenic edema [45].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kaufer, D., & Gandy, S.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Neurology
Published
2009-12-15
Volume
73
Issue
24
Pages
2052-2053
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2048064832
Cited by
21
References
3
Citations by year
2022: 2 · 2019: 2 · 2016: 1 · 2014: 5 · 2013: 3 · 2012: 1
FWCI
1.77
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Centers for Disease Control and Prevention (R49CE001495)
  • National Institute on Aging (P01AG010491, P50AG005138, P01 AG10491, R01AG022462, R21AG033387)
  • National Institute of Mental Health (R01MH086633)
  • National Institute of Biomedical Imaging and Bioengineering (K01EB009724)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
APOE ε4, bapineuzumab, Alzheimer's disease, amyloid-beta, anti-amyloid therapy, APOE genotype
MeSH terms
Alzheimer Disease, Antibodies, Monoclonal, Cognition, Heterozygote, Humans, Injections, Intravenous, Amyloid beta-Peptides, Treatment Outcome, Apolipoprotein E4, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review